Influence of diffuse nontoxic goiter on placental insufficiency, course of gestation and childbirth
Background. There are significant disorders in the functioning of the mother-placenta-fetus system in women with thyroid pathology, especially in chronic iodine deficiency. This leads to complications of pregnancy, childbirth with a threat to the newborn’s health. The purpose of the study was to investigate the effect of potassium iodide in combination with sodium selenite and cytoflavin in women with diffuse nontoxic goiter for the correction of disorders in the mother-placenta-fetus during pregnancy. Materials and methods. To assess the state of pregnancies in the period from 2012 to 2017, 159 pregnant women and their newborns, who formed two groups, were examined. The first group consisted of 79 pregnant women with diffuse nontoxic goiter, who did not receive potassium iodide and other drugs for various reasons. The second group was formed by 80 women, who received potassium iodide (200 μg/day) in combination with sodium selenite and cytoflavin. Results. Chronic fetoplacental insufficiency is registered in 21.1 % of cases, with a significant difference in its incidence in two groups of women surveyed: 27.9 % in group I and 14.3 % in group II. The level of thyroid-stimulating hormone in children born from women in the first and second groups did not differ significantly and did not exceed the normal values (4.72 ± 1.22 mIU/l and 2.73 ± 1.01 mIU/l, respectively). The concentration of thyroid-stimulating hormone in the blood of infants of the second group was 42.2 % lower than in the newborns of the first group. Conclusions. The beneficial effect of taking potassium iodide in combination with sodium selenite and cytoflavin during gestation on the development of the fetus reveals itself by a statistically significant reduction in the incidence of intrauterine complications in group II compared with group I of the study: chronic fetoplacental insufficiency (14.3 and 27.9 %, respectively; p < 0.05) and chronic fetal hypotrophy (13.8 and 28.6 %, respectively, p < 0.05).
Full Text:PDF (Українська)
Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? J Clin Endocrinol Metab. 2007 Jan;92(1):203-7. doi: 10.1210/jc.2006-1748.
Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007 Aug;92(8 Suppl):S1-47. doi: 10.1210/jc.2007-0141.
Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrinol Metab. 2010 Apr;95(4):1699-707. doi: 10.1210/jc.2009-2009.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2018